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Abstract: Despite numerous studies, the effects of ezetimibe on glucose metabolism are poorly
understood. Here, we aimed to investigate the effects of ezetimibe on glucose metabolism and the
expression of inflammatory markers. Thirteen rats were randomly assigned to an ezetimibe (n = 6)
or control group (n = 7). The control group received a high fat diet (HFD; 60 Kcal%), whereas the
ezetimibe group received an HFD (60 Kcal%) containing 160 mg/kg of ezetimibe. After 14 weeks,
adipose and liver tissues, along with plasma, were collected and comparatively analyzed. The effects
of combination therapy with ezetimibe and statins on glucose metabolism were investigated over a
1-year period using data from patients with hyperlipidemia. Several indices of glucose metabolism
partially improved in the ezetimibe group. The sizes of adipocytes and the accumulation of
pro-inflammatory cytokines were reduced in the ezetimibe group. Ezetimibe treatment induced
anti-inflammatory cytokines and fatty acid oxidation in adipocytes and reduced serum levels of
free fatty acids. Clinical data analysis revealed that statin monotherapy significantly increased
insulin resistance. However, combination therapy with ezetimibe and statins did not increase insulin
resistance. In conclusion, ezetimibe was found to reduce the sizes of adipocytes in visceral fat and
serum levels of free fatty acids, to induce fatty acid oxidation, to improve adipocytic inflammation,
and to partially improve glycemic index values.
Keywords: ezetimibe; glucose metabolism; adipocyte; insulin resistance
1. Introduction
Ezetimibe is a hyperlipidemic drug that selectively inhibits cholesterol absorption by binding to
the cholesterol carrier, Niemann-Pick C1 like 1 (NPC1L1), which is present in intestinal membranes.
Ezetimibe lowers the serum levels of cholesterol by suppressing the absorption of intestinal
cholesterol. It can be used as a supplementary or alternative drug when the hypolipidemic
effects of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are insufficient or
their usage is contraindicated. In a recently published large-scale clinical study (the IMPROVE-IT
trial), ezetimibe significantly improved hypercholesterolemia and reduced cardiovascular disease in
combination with statins; moreover, it reduced the relative risks of cardiovascular events by 6.4%,
compared to statin monotherapy [1].
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The use of statins has been linked to an increased risk of diabetes, and high-dose statin therapy
has been shown to be associated with an increased risk of new-onset diabetes, compared to treatment
with moderate doses of statins [2]. Several studies have indicated that statins increase serum glucose
levels and insulin resistance by enhancing hepatic glucose production, disrupting intracellular insulin
signaling, and hindering glucose uptake in peripheral tissues [3–7]. Meanwhile, replacing high-dose
statin therapy with ezetimibe (alone or in combination with low-dose statins) has been found to
reduce the risk of hyperglycemia and the other side effects of statins, including myotoxicity and
hepatotoxicity [8]. However, the effects of ezetimibe on glucose metabolism are poorly understood.
Although several studies have demonstrated that ezetimibe improves insulin resistance and reduces
visceral fat [9,10], some studies have reported that the use of ezetimibe increases blood glucose
levels [11]. Research has also demonstrated that hepatic steatosis, which is closely related to insulin
resistance, is improved following ezetimibe treatment in some animal models [12], but not in human
subjects [13].
There are several plausible explanations for these conflicting observations. The expression of
hepatic NPC1L1 is abundant in humans, but is very low in mice [14], and its role in glucose metabolism
remains unclear. This may have produced different results, as the effects of ezetimibe on glucose
metabolism may differ between mice and humans. Additionally, considering the mechanism by which
ezetimibe inhibits the absorption of dietary cholesterol, we suspect that effects may vary depending on
the amount of dietary cholesterol or the degree of metabolic stress.
In this study, we aimed to investigate the effects of ezetimibe on glucose metabolism both in vitro
and in vivo by administering a high fat diet (HFD) to rats expressing hepatic NPC1L1, similar to
humans. By identifying the molecular mechanisms underlying the effects of ezetimibe, we aimed
to determine whether ezetimibe therapy can be safely administered to patients with diabetes and
hepatic steatosis.
2. Experimental Section
2.1. In Vivo Study
As a pilot study, 4-week-old C57BL/6J male mice (n = 39) were fed a standard diet (5% wt/wt
fat) for 1 week to adapt to the environment. At 5 weeks of age, mice were randomly assigned to
receive HFD with ezetimibe (45 Kcal% diet containing 0.004% w/w ezetimibe) in the ezetimibe group
(n = 21) or a HFD (45 Kcal%) in the control group (n = 18). The total observation period was 19 weeks.
Weight, dietary intake, activity patterns, and health status were monitored daily throughout the
experiment. Fasting blood glucose levels were measured at baseline and after 19 weeks of drug
administration. Oral glucose tolerance test was performed after 17 weeks of drug administration,
when diabetes developed. Insulin tolerance test was performed 1 week after oral glucose tolerance test
(OGTT) (after 18 weeks of drug administration). To investigate whether ezetimibe has a direct effect on
mice liver, the expression of NPC1L1 was tested in both mice liver and HepG2 cells.
In the primary study, 5-week-old male Wistar rats (n = 13) were housed under standard conditions
at a temperature of 21 ± 2 ◦C and relative humidity of 60 ± 10% under a 12 h light/dark cycle, with
ad libitum access to food and water. The rats were randomly assigned to an ezetimibe (n = 6) or
control group (n = 7) at 6 weeks of age. The control group received an HFD (60 Kcal%), whereas the
ezetimibe group received an HFD (60 Kcal%) containing 160 mg/kg ezetimibe. The concentration of
ezetimibe (estimated 6.4 mg/kg/day) was determined based on previous experiments in rats [12,15,16].
The total observation period was 14 weeks. Body weight, food intake, activity patterns, and health
status of the animals were monitored on a daily basis throughout the duration of the experiment.
All animal procedures were performed in accordance with the guidelines of the National Institutes of
Health and pre-approved by the committee for animal care and use of Yonsei University, College of
Medicine (2017-0028).
Biomedicines 2020, 8, 512 3 of 15
An OGTT was performed after 12 weeks of administering ezetimibe. After overnight fasting
(18 h) [17], 2 g/kg of glucose was orally administered, and blood glucose levels were measured from
caudal venous blood using a portable blood glucose meter (Boehringer-Mannheim, Indianapolis,
IN, USA) after 0, 15, 30, 60, 90, and 120 min of glucose administration. An insulin tolerance test
(ITT) was performed after 10 weeks of administering ezetimibe. After 4 h of fasting [18], 1 U/kg
of insulin (Sigma-Aldrich, Cat. No. 9177C) was administered intraperitoneally, and blood glucose
levels were measured from the caudal venous blood using a portable blood glucose meter after 0,
15, 30, 60, 90, and 120 min of administering insulin. Two weeks after the OGTT, anesthesia was
performed after 18 h of fasting using a nose cone. Blood was obtained from the abdominal aorta via a
thoracotomy, after which the rats were euthanized. The blood samples were centrifuged (4000 rpm)
for 10 min, and the serum was stored at −80 ◦C. The liver and adipose tissues were excised after
euthanasia. Serum fasting glucose, stimulated glucose, fasting insulin, stimulated insulin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, triglyceride, and free fatty
acid levels were determined.
Tissue samples were washed, dehydrated, and embedded in paraffin. Some of the tissue sections
were stained with hematoxylin and eosin for histological analyses. Tissue samples were examined
under a microscope, and images were acquired using an attached digital camera. The diameters of 100
random adipocytes in each rat were measured. CellSens Entry software (Olympus, Tokyo, Japan) was
used for image analysis.
2.2. In Vitro Study
The effect of ezetimibe on glucose metabolism in HepG2 cells was compared with that in cells in
controls on the basis of the assumption that ezetimibe directly acts on hepatic NPC1L1. Ezetimibe was
dissolved in dimethyl sulfoxide before adding it to the culture medium. In all experiments, ezetimibe
was administered at a final concentration of 25 µM, and the final concentration of dimethyl sulfoxide
was ≤0.1%. The details of the materials and methods are available in the online-only Supplementary
Materials and Appendix A.
2.3. Human Study
Patient data were reviewed to investigate the effects of ezetimibe on insulin resistance in human
subjects. We reviewed the electronic medical records of patients at Severance Hospital (a tertiary care
university hospital in Seoul, Korea). The patients were aged ≥19 years, had dyslipidemia, and had
initiated treatment for dyslipidemia. The fasting insulin and fasting glucose levels of the patients
were tested before and after 1 year of pharmacotherapy between January 2006 and December 2018.
Patients in whom their antidyslipidemic or anti-diabetic medications had been altered during the
observation period were excluded from the study. Finally, data for 133 patients who satisfied the above
conditions were collected.
Age, sex, weight, height, status of diabetes, and current medications were recorded. Body
mass index values were calculated by dividing body weight by the square of the height (kg/m2).
Following an overnight fast of ≥8 h, blood samples were collected before (0 min, designated as ‘fasting’)
and after (120 min, designated as ‘stimulated’) meals to measure HbA1c, basal, glucose, stimulated
glucose, fasting insulin, and other biochemical parameters. Insulin sensitivity was assessed using the
homeostasis model assessment of insulin resistance (HOMA-IR) index [19]. The Ethics Committee of
the Yonsei University College of Medicine approved this study (4-2018-1038).
2.4. Statistical Analysis
All categorical variables are expressed numerically as a proportion and were compared by
χ2 analysis. Continuous variables were compared using the Wilcoxon-Mann-Whitney U test or
Kruskal-Wallis test. The Wilcoxon signed-rank test was used to compare the clinical data before
and after treatment. All statistical analyses were performed using IBM SPSS statistical software for
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Windows, version 25.0 (IBM, Armonk, NY, USA). For statistical analysis, p values <0.05 were considered
statistically significant.
3. Results and Discussion
We performed a pilot study in mice, and details on the materials and methods thereof are available
as an online-only supplement. Therein, treatment with ezetimibe did not significantly affect overall
glycemic patterns. However, ITTs revealed a significant reduction in blood glucose levels in the
ezetimibe group at 30 and 60 min, compared to those in the control group (Supplementary Figure S1).
In order to investigate whether ezetimibe has direct effects on mice liver, the expression of NPC1L1
was determined in both mice liver tissue and HepG2 cells. As depicted in Supplementary Figure S2a,
there was no evidence of the expression of NPC1L1 in the mice liver. From the results of this pilot study,
we hypothesized that ezetimibe could improve insulin resistance without directly acting on the liver.
Further, we confirmed the hepatic expression of NPC1L1 in HepG2 cells or rat liver (Supplementary
Figure S2b). NPC1L1 is not only present in the intestinal membrane, but also in hepatocytes. It is
involved in the reabsorption of cholesterol released into bile [20]. The role and mechanisms of action
of hepatic NPC1L1 are yet to be fully understood. Although NPC1L1 is rarely expressed in mice
hepatocytes, it is expressed in the liver of both rats and humans [14]. Thus, we investigated the effect of
ezetimibe on glucose metabolism following the administration of HFD in a rat model with the hepatic
expression of NPC1L1, similar to human subjects.
The characteristics of the rat model are described in Supplementary Table S1. There was no
difference in the body weights between the experimental groups at baseline. At the end of the treatment
period (14 weeks), there was no difference in body weight or body weight gain between the groups.
Although liver weight decreased significantly in the ezetimibe group (11.2 ± 1.0 g), compared to that
in the control group (13.0 ± 1.4 g) (p = 0.015), there was no significant difference in the liver weight,
total body weight (%), or weight of the perigonadal fat between the ezetimibe and control groups
(all p > 0.05). Over the 14-week study period, there was no difference in body weight gain between the
ezetimibe and control groups (Figure 1a), and there was no statistical difference in overall food intake
between the groups (Figure 1b). In the rat model, the results of OGTTs revealed that glucose tolerance
in the ezetimibe group significantly improved after 15 min of glucose administration, compared to
that in the control group (p < 0.022, Figure 1c,e). The AUC value of the OGTT was lower for the
ezetimibe group than for the control group; however, the difference was not statistically significant
(Figure 1g, p = 0.063). Insulin tolerance in the ezetimibe group improved more after 15 min of insulin
administration, compared to that in the control group (p = 0.010, Figure 1d,f). The AUC value of
ITTs was lower for the ezetimibe group than for the control group; however, the difference was not
statistically significant (Figure 1h, p = 0.063).
Serum levels of triglycerides and free fatty acids were significantly lower in the ezetimibe group
than in the control group (all p < 0.01, Figure 2a,b). The levels of aspartate aminotransferase and alanine
aminotransferase decreased in the ezetimibe group (all p < 0.05, Figure 2c,d). However, the difference
in the levels of hepatic triglycerides between the ezetimibe and control groups was not statistically
significant (p = 0.886, Figure 2e).
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Figure 1. Effects of ezetimibe on oral glucose tolerance test (OGTT) and insulin tolerance test (ITT). 
(a) Gain in body weight, (b) cumulative food intake (Kcal/animal) (c) OGTT, (d) ITT, (e) OGTT after
15 min of glucose administration, (f) ITT after 15 min of glucose administration, (g) AUC of OGTT,
and (h) AUC of ITT. Compared using the Wilcoxon-Mann-Whitney U test; * p < 0.05. OGTT; oral
glucose tolerance test, ITT; insulin tolerance test.
Serum levels of triglycerides and free fatty acids were significantly lower in the ezetimibe group 
than in the control group (all p < 0.01, Figure 2a,b). The levels of aspartate aminotransferase and 
alanine aminotransferase decreased in the ezetimibe group (all p < 0.05, Figure 2c,d). However, the 
Figure 1. Effects of ezetimibe on oral glucose tolerance test (OGTT) and insulin tolerance test (ITT).
(a) Gain in body weight, (b) cumulative food intake (Kcal/animal) (c) OGTT, (d) ITT, (e) OGTT after
15 min of glucose administration, (f) ITT after 15 min of glucose administration, (g) AUC of OGTT,
and (h) AUC of ITT. Compared using the Wilcoxon-Mann-Whitney U test; * p < 0.05. OGTT; oral glucose
tolerance test, ITT; insulin tolerance test.
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(AST) levels, alanine aminotransferase (ALT) levels, and hepatic triglyceride levels. (a) Triglyceride 
levels, (b) free fatty acid levels, (c) AST (IU/L) levels, (d) ALT (IU/L) levels, and (e) hepatic triglyceride 
(mM/g) levels. The hepatic triglyceride levels were measured using a triglyceride quantification kit 
(Abcam, Cat. No. ab65336). Compared using the Wilcoxon-Mann-Whitney U test; * p < 0.05, ** p < 0.01. 
AST; aspartate aminotransferase, IU/L; international units per liter, ALT; alanine aminotransferase. 
Several of the glucose metabolism indices partially improved in the rats in the ezetimibe group. 
However, these differences did not lower systemic blood glucose levels, and the observed 
improvement in hepatic steatosis was not statistically significant. The features of non-alcoholic fatty 
liver disease are closely related to those of metabolic syndrome, including obesity and insulin 
resistance. Improvement in insulin resistance inhibits sterol regulatory element binding protein-1c 
and fatty acid synthase [21], which improve hepatic steatosis. A few studies have reported that fatty 
liver also improves in human subjects following ezetimibe treatment [11,22]. However, the findings 
of some studies on improvement in fatty liver in human subjects following ezetimibe therapy are 
unclear. By measuring hepatic fat fractions by magnetic resonance imaging proton density, Loomba 
and colleagues reported no significant improvement in hepatic steatosis following ezetimibe 
treatment [13]. In the present study, the experimental period of the present study (14 weeks) may not 
have been long enough to induce hepatic steatosis; therefore, further studies conducted over a longer 
study period are necessary. 
The sizes of adipocytes in the ezetimibe group (99.8 ± 23.4 µm) were significantly smaller than 
those in the control group (112.2 ± 25.1 µm) (p < 0.001, Figure 3a). The levels of pro-inflammatory 
cytokines IL-1β, MCP1, and IL-6 significantly decreased in the ezetimibe group (all p <0.05). 
Figure 2. Effects of ezetimibe on triglyceride levels, free fatty acid levels, aspartate aminotransferase
(AST) levels, alanine aminotransferase (ALT) levels, and hepatic triglyceride levels. (a) Triglyceride
levels, (b) free fatty acid levels, (c) AST (IU/L) levels, (d) ALT (IU/L) levels, and (e) hepatic triglyceride
(mM/g) levels. The hepatic triglyceride levels were measured using a triglyceride quantification kit
(Abcam, Cat. No. ab65336). Compared using the Wilcoxon-Mann-Whitney U test; * p < 0.05, ** p < 0.01.
AST; aspartate aminotransferase, IU/L; international units per liter, ALT; alanine aminotransferase.
Several of the glucose metabolism indices partially improved in the rats in the ezetimibe group.
However, these differences did not lower systemic blood glucose levels, and the observed improvement
in hepatic steatosis was not statistically significant. The features of non-alcoholic fatty liver disease are
closely related to those of metabolic syndrome, including obesity and insulin resistance. Improvement
in insulin resistance inhibits sterol regulatory element binding protein-1c and fatty acid synthase [21],
which improve hepatic steatosis. A few studies have reported that fatty liver also improves in human
subjects following ezetimibe treatment [11,22]. However, the findings of some studies on improvement
in fatty liver in human subjects following ezetimibe therapy are unclear. By measuring hepatic
fat fractions by magnetic resonance imaging proton density, Loomba and colleagues reported no
significant improvement in hepatic steatosis following ezetimibe treatment [13]. In the present study,
the experimental period of the present study (14 weeks) may not have been long enough to induce
hepatic steatosis; therefore, further studies conducted over a longer study period are necessary.
The sizes of adipocytes in the ezetimibe group (99.8 ± 23.4 µm) were significantly smaller than
those in the control group (112.2 ± 25.1 µm) (p < 0.001, Figure 3a). The levels of pro-inflammatory
cytokines IL-1β, MCP1, and IL-6 significantly decreased in the ezetimibe group (all p <0.05). Conversely,
the levels of anti-inflammatory cytokines IL-10 and Arg-1 significantly increased in the ezetimibe group
(all p < 0.05, Figure 3b). There was no significant change in the mRNA levels of the genes associated with
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lipogenesis (Figure 3c–e) or lipolysis (Figure 3f–g) following ezetimibe treatment. However, the mRNA
levels of pyruvate dehydrogenase kinase-2, which is associated with fatty acid oxidation, significantly
increased following treatment with ezetimibe (p < 0.001, Figure 3h). The expression of long-chain
acyl-CoA dehydrogenase, which plays an important role in β-oxidation, also tended to increase,
however, the change was not statistically significant (Figure 3i).
Cholesterol, which is absorbed by the intestines, is transferred as chylomicrons to the blood via
lymphatic circulation and is distributed throughout the body via systemic circulation. Chylomicron
levels increase after meals and contribute to the development of atherosclerosis. This reduces the
expression of low-density lipoprotein (LDL) receptors in the liver and increases the levels of LDL
cholesterol [15]. Lipid overload in obesity is associated with adipocyte dysfunction, inflammation,
macrophage infiltration, and decreased fatty acid oxidation [23]. A previous study on monkeys
demonstrated that the sizes and inflammatory status of visceral adipocytes change when the dietary
intake of cholesterol is increased [24], and as expected, the action of ezetimibe, limiting the intestinal
absorption of dietary cholesterol, enhanced fatty acid oxidation and relieved inflammatory reactions
in visceral adipose tissues in this study. Previous studies have reported that the accumulation of
cholesterol in adipocytes is correlated with an increased risk of metabolic syndrome and cardiovascular
diseases [25] and that the use of ezetimibe reduces cardiovascular risks [1]. While the cardiovascular
benefits of ezetimibe are primarily mediated by lowering LDL cholesterol levels [1], the results of the
current study suggest that a reduction in cholesterol accumulation in adipocytes may also reduce
cardiovascular risk.
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 Figure 3. Effects of ezetimibe on the sizes of adipocytes, markers of inflammation, and genes involved
in lipogenesis, lipolysis, and β-oxidation. (a) The effects of ezetimibe on the sizes of adipocytes were
compared using two-sample t-test for a total of 1,300 adipocytes (n = 100 per animal). The sizes of the
adipocytes were markedly reduced in the ezetimibe group, compared to those in the control group
(p < 0.001). (b) The effects of ezetimibe on markers of inflammation: (upper panel) pro-inflammatory
cytokines and (lower panel) anti-inflammatory cytokines. (c) LPL, (d) Lipin1, (e) Perilipin, (f) PEPCK,
(g) ATGL, (h) PDK2, and (i) LCAD. Compared using the Wilcoxon-Mann-Whitney U test; * p < 0.05.
LPL; lipoprotein lipase, PEPCK; phosphoenolpyruvate carboxykinase, ATGL; adipose triglyceride
lipase, PDK2; pyruvate dehydrogenase kinase-2, LCAD; long-chain acyl-CoA dehydrogenase.
In this study, we observed that insulin resistance improved and that the levels of free fatty acids
decreased following ezetimibe treatment. Free fatty acids induce insulin resistance in peripheral
tissues [26]. Previous studies have demonstrated that ezetimibe inhibits not only dietary cholesterol
absorption, but also dietary free fatty acids absorption [27]. Additionally, an increase in adipocytic
inflammation has been shown to be associated with adipocyte hypertrophy, which is associated
with increased insulin resistance [28]. These actions may be particularly beneficial for patients with
diabetes. A meta-analysis by Hong and coworkers reported that ezetimibe-statin combination therapy
is associated with greater cardiovascular benefits in patients with diabetes than in those without
diabetes [29].
To investigate whether ezetimibe has direct effects on the liver, we evaluated phosphorylation levels
of Akt in HepG2 cells after 15 min of stimulation with insulin to analyze the direct effects of ezetimibe
on the hepatic insulin response. The difference in the levels of Akt phosphorylation in the HepG2 cells
in the control and ezetimibe groups was not statistically significant (all p > 0.05, Supplementary Figure
S3a). We evaluated the levels of glucose 6-phosphatase and phosphoenolpyruvate carboxykinase
following stimulation with low (5.5 mM) concentrations of glucose to analyze the direct effect of
ezetimibe on gluconeogenesis. Western blotting revealed that there was no significant difference in
the levels of G6pase or PEPCK in the HepG2 cells in the control and ezetimibe groups (all p > 0.05,
Supplementary Figure S4). However, PCR analyses revealed that the levels of G6pase and PEPCK
significantly increased at several instances during ezetimibe treatment (Supplementary Figure S3b,c).
PCR analyses revealed that hepatic glucose outflow increased significantly following ezetimibe
treatment (Supplementary Figure S5).
In this study, the results of in vitro experiments revealed that insulin signaling and
gluconeogenesis in hepatocytes did not improve significantly following ezetimibe treatment;
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however, gluconeogenesis and glucose outflow in human hepatocytes increased in the ezetimibe
treatment group. This demonstrated that an increase in gluconeogenesis resulting from the direct
action of ezetimibe on the liver may ameliorate its beneficial effects on systemic glucose metabolism.
Although we observed an improvement in insulin resistance, the overall effect of ezetimibe on
dysglycemia was not significant. In previous mouse model studies, the use of ezetimibe was associated
with an improvement in dysglycemia [30]. However, the effects of ezetimibe on glucose metabolism
has not been clearly reported in human subjects. Some randomized controlled trials on ezetimibe
had to be discontinued owing to increases in blood glucose levels during the study period [11].
Kurano and coworkers reported that hepatic NPC1L1 is involved in suppressing gluconeogenesis [31].
In humans rich in hepatic NPC1L1 expression, the use of ezetimibe may lead to an increase in hepatic
gluconeogenesis. This could be the reason why the use of ezetimibe appears to improve insulin
resistance, but does not elicit a significant improvement in dysglycemia
We further investigated whether the observed effect of ezetimibe on glycemic indices can be
confirmed through clinical data. In total, 133 patients with dyslipidemia who had initiated medication
for dyslipidemia and had undergone tests for both fasting insulin and fasting glucose levels before
and after 1 year of pharmacotherapy were included in this study. The patients were classified into
the statin monotherapy group (n = 90, 67.7%) and the ezetimibe combination group (n = 43, 32.3%).
The latter was sub-classified into ezetimibe add-on statin (n = 13, 9.8% of total) and ezetimibe start with
statin (n = 30, 22.6% of total) subgroups. The baseline characteristics of the patients are summarized in
Table 1. The study population included 66.9% women, and 11.3% of the patients had type 2 diabetes.
All of the patients were of Asian descent. Both groups had similar baseline characteristics, with the
exception of fasting glucose, total cholesterol, and levels of LDL cholesterol. There were differences in
the cholesterol levels at the beginning of each treatment, possibly owing to the fact that each of the
drugs had different indications: fasting glucose levels were higher in the ezetimibe add-on statin group
than in the statin monotherapy group (all p < 0.05, Table 1).
Table 1. Baseline characteristics of the study population.
Combination Therapy Monotherapy
p ValueEzetimibe Add on
Statin (n = 13)
Ezetimibe Start
with Statin (n = 30)
Statin Monotherapy
(n = 90)
Age (years) 61.0 (16.5) 58.5 (11.8) 58.0 (10.0) 0.467
Female (%) 9 (69.2) 17 (56.7) 63 (70.0) 0.398
Diabetes (%) 2 (15.4) 3 (10.0) 10 (11.1) 0.873
BMI (kg/m2) 24.0 (6.9) 24.7 (3.9) 24.0 (3.7) 0.658
Glucose, fasting (mg/dL) 109.0 (27.0) 105.0 (15.3) 99.0 (17.0) * 0.008
Glucose, stimulated
(mg/dL) 123.5 (79.0) 118.0 (40.0) 111.0 (30.0) 0.492
Insulin, fasting (uU/mL) 7.3 (9.2) 6.1 (3.1) 6.2 (3.6) 0.126
HOMA-IR 2.0 (2.5) 1.6 (0.9) 1.5 (0.9) 0.060
HbA1c (%) 6.1 (1.1) 5.8 (1.0) 5.9 (0.4) 0.110
AST (IU/L) 22.0 (5.5) 19.5 (6.3) 21.0 (8.0) 0.401
ALT (IU/L) 18.0 (17.5) 18.5 (7.8) 18.0 (9.5) 0.743
Total cholesterol (mg/dL) 184.0 (38.5) 259.0 (40.5) * 232.0 (47.5) *,† <0.001
Triglycerides (mg/dL) 113.0 (73.5) 125.0 (96.5) 132.0 (68.0) 0.989
HDL cholesterol (mg/dL) 50.0 (14.0) 54.0 (13.5) 52.0 (15.0) 0.429
LDL cholesterol (mg/dL) 112.6 (29.6) 169.6 (36.2) * 150.2 (52.0) *,† <0.001
BMI, body mass index; HOMA, homeostatic model assessment; IR, insulin resistance; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Kruskal-Wallis test, Dunn procedure; NOTE. Bold text indicates p values < 0.05; * p values < 0.05 vs. ezetimibe add
on statin group, by post hoc analyses (Dunn procedure); † p values < 0.05 vs. ezetimibe start with statin group,
by post hoc analyses (Dunn procedure), p values < 0.05.
There was a significant reduction in total cholesterol and LDL cholesterol levels in both groups,
compared to those at baseline (all p < 0.05, Supplementary Table S2). The levels of fasting glucose,
Biomedicines 2020, 8, 512 10 of 15
stimulated glucose, fasting insulin, and HOMA-IR significantly increased in the statin monotherapy
group (all p < 0.05, Table 2). Intention-to-treat analysis revealed that there were no differences between
the groups with respect to all metabolic indices (all p > 0.05). Insulin resistance significantly increased in
the statin monotherapy group after 1 year (+0.33, p = 0.002); however, there was no significant increase in
insulin resistance in the ezetimibe combination group (+0.14, p = 0.530). Additionally, insulin resistance
in the ezetimibe add-on statin group tended to decrease, as calculated by HOMA-IR (−0.24, p = 0.382,
Supplementary Figure S6).
Table 2. Comparison of changes in the parameters of patients treated with ezetimibe combination or
statins after 1 year.
Ezetimibe Combination (n = 43) Statin Monotherapy (n = 90) Differencebetween Groups
Baseline Post-Treatment p Value Baseline Post-Treatment p Value p Value
Glucose, fasting
(mg/dL) 106.0 (18.0) 105.0 (20.0) 0.296 99.0 (17.0) 101.0 (17.3) 0.021 0.996
Glucose, stimulated
(mg/dL) 118.0 (58.0) 127.0 (52.5) 0.946 111.0 (30.0) 132.0 (54.0) 0.016 0.117
Insulin, fasting
(uU/mL) 7.0 (3.8) 7.3 (4.6) 0.828 6.2 (3.6) 7.3 (4.1) 0.003 0.066
HOMA-IR 1.7 (0.9) 1.8 (1.3) 0.923 1.5 (0.9) 1.8 (1.1) 0.002 0.109
HbA1c (%) 6.0 (0.9) 5.9 (0.8) 0.793 5.9 (0.4) 5.9 (0.3) 0.758 0.865
AST (IU/L) 21.0 (6.0) 23.0 (9.0) 0.003 21.0 (8.0) 23.0 (7.0) 0.009 0.825
ALT (IU/L) 18.0 (9.0) 23.0 (21.0) 0.012 18.0 (9.5) 21.0 (13.0) 0.003 0.694
Total cholesterol
(mg/dL) 241.0 (61.0) 167.0 (47.0) <0.001 232.0 (47.5) 168.5 (40.3) <0.001 0.850
Triglycerides
(mg/dL) 125.0 (84.0) 116.5 (71.0) 0.347 132.0 (68.0) 110.5 (76.8) 0.014 0.629
HDL cholesterol
(mg/dL) 53.0 (15.0) 51.5 (18.3) 0.175 52.0 (15.0) 52.0 (16.3) 0.077 0.830
LDL cholesterol
(mg/dL) 154.0 (60.4) 82.9 (38.8) <0.001 150.2 (52.0) 90.0 (30.2) <0.001 0.566
The data are presented as a median (IQR), and the p values were obtained from the Wilcoxon signed-rank test.
The difference in p values was determined via intention-to-treat analysis.
The analysis of clinical data obtained from human subjects revealed that statin monotherapy
significantly increased insulin resistance. In contrast, the use of ezetimibe in combination with statins
did not increase insulin resistance. A recent meta-analysis revealed that ezetimibe treatment does not
improve dysregulated glycemic control in human subjects [32]. However, it also has been reported
that the use of ezetimibe improves glucose-related indicators, including insulin resistance [33] and
visceral fat [9]. In addition, through a combination with ezetimibe, a sufficient cholesterol lowering
effect can be expected even when a relatively small dose of statin is used [34]. Therefore, improved
glucose metabolism through statin reduction can also be expected with the inclusion of ezetimibe.
This study has several limitations. First, insulin secretion function by studying pancreatic beta
cells or the effects of ezetimibe on skeletal muscle, which consumes a high portion of glucose in the
body, were not evaluated in this study. Since the concentration of ezetimibe in rats was higher than
that for human daily use (10 mg/day), the effect of ezetimibe on glucose metabolism in rats could be
amplified. Second, the study population was not large enough; therefore, several analyses could not be
performed. For this reason, we are unable to exclude the possibility that the statistically insignificant
results obtained here may have clinical significance. Considering the relatively short duration of this
study, further studies are necessary to determine whether the long-term use of ezetimibe improves
dysglycemia. Third, owing to the limited expression of NPC1L1 in specific organs, it was difficult
to explain how ezetimibe indirectly affected adipocytes. Additionally, the study on human subjects
was retrospectively designed. Thus, important data, including body weight and waist circumference,
were not determined to ensure that these data are not reflected in the results. However, the importance
of this study lies in the fact that it is the first to describe changes in adipocytes following ezetimibe
treatment, owing to its effect on glucose metabolism. The results of this study suggest that ezetimibe
can be safely administered to patients with diabetes.
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4. Conclusions
The use of ezetimibe reduced the sizes of adipocytes in visceral fat. Furthermore, ezetimibe reduced
the accumulation of pro-inflammatory cytokines and induced the production of anti-inflammatory
cytokines within adipocytes, leading to increased fatty acid oxidation; reduced levels of free fatty acids;
and improved insulin resistance. However, there was no significant effect on systemic glucose control,
which was confirmed from the retrospectively designed clinical study.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-9059/8/11/512/s1:
Figure S1. Systemic glucose metabolism evaluated with oral glucose tolerance test and insulin tolerance test.
Figure S2. The expression of hepatic NPC1L1 on mice and rat liver. Figure S3. Effects of ezetimibe on markers of
gluconeogenesis in HepG2 cells, evaluated by Western blot. Figure S4. Effects of ezetimibe on glucose outflow
in HepG2 cells. Figure S5. Changes in homeostatic model assessment of insulin resistance values. Figure S6.
Changes of homeostatic model assessment of insulin resistance in patients of each group. Table S1. Characteristics
of the animals in the control group (HFD) and ezetimibe group (HFD + ezetimibe). Table S2. Changes in glycemic
indicators and cholesterol levels before and after treatment.
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Appendix A. Materials and Methods (Detailed)
Appendix A.1. In Vivo Study
Thirteen 5-week-old male Wistar rats were housed under standard conditions (21 ± 2 ◦C, 60 ± 10%
humidity, 12 h light/dark cycle) with ad libitum access to food and water. The rats were randomly
assigned to either the ezetimibe group (n = 6) or control group (n = 7) at 6 weeks of age. The control
group was fed a high fat diet (HFD; 60 Kcal%) and the ezetimibe group was fed a HFD (60 Kcal%)
containing ezetimibe (160 mg/kg). The total observation period was 14 weeks. Weight, dietary intake,
activity patterns, and health status were monitored daily throughout the experiment.
All animal procedures were performed in accordance with the guidelines of the National Institutes
of Health and pre-approved by the animal care and use committee of Yonsei University, College of
Medicine (2017-0028).
Appendix A.1.1. Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Oral glucose tolerance test (OGTT) was performed after 12 weeks of drug administration.
After fasting for 18 h, 2 g/kg of glucose was administered orally, and blood glucose levels were
measured from caudal venous blood using a portable blood glucose meter (Boehringer-Mannheim,
Indianapolis, IN, USA) at 0, 15, 30, 60, 90, and 120 min post glucose administration.
Insulin tolerance test (ITT) was performed after 10 weeks of drug administration. After fasting for
4 h, 1 U/kg of insulin (Sigma-Aldrich, Cat. No. 9177C) was administered intraperitoneally, and blood
glucose levels from caudal venous blood were measured by a portable blood glucose meter at 0, 15, 30,
60, 90, and 120 min post insulin administration.
Appendix A.1.2. Blood and Tissue Sampling
Two weeks after OGTT, after 18 h of fasting, anesthesia was performed using a nose cone.
Blood was obtained from the abdominal aorta by thoracotomy. The rat was then euthanized. The blood
was centrifuged for 10 min, and the serum was stored at −80 ◦C. Post euthanasia, the liver and fat tissue
were excised. The liver and fat tissue samples were rapidly frozen with nitrogen solution and stored at
Biomedicines 2020, 8, 512 12 of 15
−80 ◦C. Some liver and fat tissue samples were fixed in 4% paraformaldehyde (Tech & Innovation Co.,
Ltd., Chuncheon, South Korea, Cat. No. BPP-9004-004LR) solution for more than 48 h and used for
histological analysis.
Appendix A.1.3. Measurement of Metabolic Parameters and Inflammation Markers (Blood)
Serum fasting glucose concentration, stimulated glucose, fasting insulin, stimulated insulin
(Morinaga Ultra Sensitive Rat Insulin ELISA Kit [Morinaga, Yokohama, Japan, Cat. No. M1103]),
aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, triglyceride,
and free fatty acid levels were determined.
Appendix A.1.4. Hematoxylin and Eosin (H&E) Staining
Tissue samples were washed, dehydrated, and embedded in paraffin. Some were stained with
hematoxylin and eosin (H&E) for observation of histological structures. Tissue samples were examined
under a microscope, and images were acquired using an attached digital camera. CellSens Entry
software (Olympus, Tokyo, Japan) was used for image analysis.
Appendix A.2. In Vitro Study
The effect of ezetimibe on glucose metabolism in HepG2 cells was compared assuming a
direct action of ezetimibe on hepatic NPC1L1. Hepatocellular carcinoma (HepG2) cell lines were
cultured in Dulbecco’s Modified Eagle’s Medium (Thermo Scientific, Waltham, MA, USA, SH30243.01)
containing 10% fetal bovine serum (Thermo Scientific, SH30071.03), 100 U/mL penicillin, and 100 mg/mL
streptomycin (Thermo scientific, SV30010) in a 5% CO2 incubator at 37 ◦C.
Ezetimibe was dissolved in dimethyl sulfoxide before dilution in culture medium. In all
experiments, the final ezetimibe concentration was 25 uM, and the final dimethyl sulfoxide concentration
was ≤0.1%.
Western Blot
Cells and tissues were lysed in radioimmunoprecipitation assay buffer, containing of 20 mM
tris (hydroxymethyl) aminomethane hydrochloride (pH 7.5), 150 mM sodium chloride (NaCl),
1 mM disodium ethylenediaminetetraacetate dihydrate, 1 mM ethylene glycol bis(-aminoethyl
ether)-N,N,N′,N′-tetraacetic acid, 1% Nonidet P-40, 1% sodium deoxycholate, 2.5 mM sodium
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM sodium orthovanadate, 1 µg/mL leupeptin
(BRI-9010-010M, Tech & Innovation Co., Ltd.), and protease inhibitor and phosphatase cocktail (Thermo
Scientific, 78440). Protein samples were separated using 10% polyacrylamide gels and transferred to
polyvinylidene fluoride membranes (Millipore, PVH00010). The membranes were incubated with
primary antibodies to measure the expression of the following proteins: G6Pase (Santacruz, Cat. No.
sc-25840), phosphoenolpyruvate carboxykinase (PEPCK, Santa Cruz Biotechnology, Cat. No. sc-32879),
NPC1L1 (Invitrogen, Cat. No. PA1-16800), total Akt (Cell Signaling, Cat. No. 4691S), and p-Akt (Ser473,
Cell Signaling, Cat. No. 4060S). Anti-mouse IgG, horseradish peroxidase (HRP)-linked antibody (Santa
Cruz Biotechnology, Cat. No. sc-516102), and anti-rabbit IgG, HRP-linked antibody (Cell Signaling,
7074S) were used as secondary antibodies. NPC1L1 expression in liver tissue was also confirmed.
Appendix A.3. Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from tissues and cells with TRIzol reagent (15596–018, Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions, and 2 mg of total RNA was reverse transcribed
to cDNA using the High Capacity cDNA Reverse Transcription kit (4368814, Applied Biosystems,
Foster City, CA, USA). The resultant cDNA was amplified in the ABI 7500 sequence detection system
(4350584, Applied Biosystems, Foster City, CA, USA) using Power SYBR Green PCR Master Mix
(4367659, Applied Biosystems, Foster City, CA, USA) with the following cycling conditions: 40 cycles
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of 95 ◦C for 5 s, 58 ◦C for 10 s, and 72 ◦C for 20 s. Target gene expression was normalized to that
of GAPDH (glyceraldehyde-3-phosphate dehydrogenase, and quantitative analyses were conducted
using the 44cycle threshold method and StepOne Software version 2.2.2.
The primer sets used for quantitative polymerase chain reaction (qPCR) are as follows:
Rat Gapdh forward, 5′–ATGGCACAGTCAAGGCTGAGA–3′
Rat Gapdh reverse, 5′–CGCTCCTGGAAGATGGTGAT–3′
Rat IL-1 beta forward, 5′–CACCTCTCAAGCAGAGCACAG–3′
Rat IL-1 beta reverse, 5′–GGGTTCCATGGTGAAGTCAAC–3′
Rat MCP-1 forward, 5′–TGTCTCAGCCAGATGCAGTTAAT–3′
Rat MCP-1 reverse, 5′–CATCTTGCCAGTGAATGAGTAGC–3′
Rat IL-6 forward, 5′–GGGACTGA TGTTGTTGACAGCC–3′
Rat IL-6 reverse, 5′–CATATGTAA TTAAGCCTCCGACTTGTG–3′
Rat IL-4 forward, 5′–TCTCACGTCACTGACTGTA–3′
Rat IL-4 reverse, 5′–CTTTCAGTGTTGTGAGCGT–3′
Rat IL-10 forward, 5′–GTCATCGATTTCTCCCCTGTGA–3′
Rat IL-10 reverse, 5′–TTCATGGCCTTGTAGACACCTTT–3′
Rat Agr-1 forward, 5′–CCTATGCGTCATTTGGGTGG–3′
Rat Agr-1 reverse, 5′–TACACGATGTCCTTGGCAGA–3′
(HepG2 cell, Human)
Human PEPCK forward, 5′–GAGAGAACTCCAGGGTGCTG–3′
Human PEPCK reverse, 5′–TTGCTTCAAGGCAAGGATCT–3′
Human G6pase forward, 5′–TTTGGGATCCAGTCAACACA–3′
Human G6pase reverse, 5′–CAGATGGGGAAGAGGACGTA–3′
Human Gapdh forward, 5′–TTTGGGATCCAGTCAACACA–3′
Human Gapdh reverse, 5′–CAGATGGGGAAGAGGACGTA–3′
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